Showing: 1 - 2 of 2 RESULTS

Sidero Bioscience Announces Agreement with SRS Life Sciences for Commercialization of BioFe for Iron Deficiency

Sidero Bioscience, LLC, (Hershey, PA) a clinical stage biotechnology company targeting human digestive health, today announces the execution of a term sheet agreement with SRS Life Sciences PTE. LTD, (Singapore) a leading life sciences company. The agreement provides SRS exclusive rights for sales, marketing, and distribution of Sidero’s patented biologic iron, BioFeTM, for the management of iron deficiency and related disorders in India and Southeast Asia.

“This agreement illustrates the excellent partners and licensing opportunities available for our robust and intuitive BioFe technology,” noted Darren Wolfe, Ph.D., President & CEO, Sidero, adding “Iron Deficiency remains a massive global unmet medical need, one that BioFe addresses with natural biology instead of chemicals. We are encouraged by the eagerness of the SRS team to work with us and expect a binding agreement in the near term.”

“At SRS Life Sciences, we exist to change what’s possible for the health of the 6 billion people living in emerging nations. We continuously identify the most pressing unmet healthcare needs so we can be first to deliver products and solutions that lessen the burden of disease,” states Suchet Rastogi, CEO, SRS Life Sciences. Mr. Rastogi continues, “With BioFe, our initial target is to move the needle on the 468 million women suffering from anemia.”

Iron Deficiency (ID), the most common and widespread global nutritional disorder, affects over 2 billion people and causes about 1 million deaths/year (predominantly in Africa/Southeast Asia). The WHO estimates a staggering $2 trillion annual global economic cost due to micronutrient deficiencies, with iron being the most common. ID, which frequently progresses to Iron Deficiency Anemia (IDA), is associated with numerous medical conditions and symptoms, affecting all ages – prenatal to elderly. In the young, ID impedes motor and mental development leading to lifelong physical and cognitive deficiencies. In adults, ID causes fatigue, reduced work capacity, and reduced quality of life among many other symptoms. Iron deficiency is also linked to restless leg syndrome (RLS), hearing deficits, and heart failure and kidney disease morbidity. Significantly, even mild Iron Deficiency leads to decreased physical/athletic performance and also decreased intellectual/cognitive performance.

James Connor, Ph.D., Founder and Chairman of the Sidero Board, states, “In partnership with SRS, we strive to provide a safe, effective, and cost-efficient treatment option for iron deficiency. The SRS health team understands the global impact of ID/IDA and are experts in launching transformational technologies, like BioFe, to fill significant unmet medical needs.”

About Sidero Bioscience

Sidero is advancing disruptive technologies utilizing the patented SiderosorbTM platform that employs nutritional Baker’s yeast, Saccharomyces cerevisiae, to provide therapeutic proteins/complexes to improve human health. BioFeTM is a nutritional yeast strain expressing very high levels of H-Ferritin, FTH1, a natural iron transport and storage protein. An illustrative example of the natural biology of the Ferritin/Iron complex is its presence in human breast milk, providing nursing infants the readily adsorbed iron required for growth and development without gastrointestinal upset. Sidero is currently preparing manuscripts detailing the preclinical and clinical development

In Optic Myelitis, Consider Biotinidase Deficiency

The problem of a rare enzyme disorder being mistakenly diagnosed as neuromyelitis optica spectrum disorder (NMOSD) is highlighted in a new case report involving a child.

Dr Jonathan Santoro

“Biotinidase deficiency is a rare, autosomal recessive, metabolic disorder associated with mutations in the BTD gene,” the authors, Jonathan Santoro, MD, and Kelli Paulsen, RN, Children’s Hospital Los Angeles, Los Angeles, California, explain.

“Clinical features are heterogeneous, although optic neuropathy and myelitis have been reported in children. These clinical features can mimic NMOSD,” they add.

The case is outlined in a research letter published online on October 5 in JAMA Neurology.

The authors describe a 13-year-old girl who presented with symptoms of NMOSD ― simultaneous paraparesis and bilateral vision loss. Imaging showed bilateral signal prolongation in the optic nerves. She was treated with intravenous methylprednisolone for NMOSD, but her symptoms worsened.

Repeat imaging at 1 year showed resolution of signal in the spinal cord and optic nerve atrophy, but visual deficits continued. Serum and cerebrospinal fluid studies remained unremarkable, but profound biotinidase enzyme activity deficiency was identified, as were three mutations in the BTD gene.

The patient was treated with biotin supplementation, and by 3 months, her visual acuity had improved. She continues receiving biotin therapy and has had no further relapses, Santoro and Paulsen report.

“Biotinidase deficiency is a very rare disorder which typically manifests in young children as epilepsy and intellectual disability,” Santoro told Medscape Medical News.

“We sometimes see biotinidase deficiency in adults as a mimic of optic neuritis or transverse myelitis. These are inflammatory diseases caused by autoimmune antibodies, but in a very small percentage of patients, similar symptoms may be present, and on further work-up, no inflammation or antibodies are found, and then other causes are looked for, one of which is biotinidase deficiency,” he explained.

“In adults, this is very rare, but it is an established condition. In children, this presentation of biotinidase deficiency is even more rare. We don’t know the incidence, as we we’re not generally looking for it,” Santoro said.

“Pediatric neurologists are trained to think of biotinidase deficiency to be associated with seizures in infancy, normally picked up in the first few months of life,” he said. “Outside of infancy, it is almost never tested for,” he added.

The authors note than 10 similar cases of biotinidase deficiency mimicking NMOSD have been reported in the literature. “Our case mirrored these previously reported cases,” Santoro said.

“What we are seeing is patients who seem to have neuromyelitis optica [NMO] or a similar inflammatory disorder characterized by vision loss with possibly some other effects, such as gait or walking issues, but they do not have the AQP4 or MOG antibodies that are present in NMO. And they do not show high white blood cell counts in spinal fluid that are seen in NMO,” he said.

“If this is the case, then we have to start to think outside the box, and biotinidase deficiency is one possibility,” he added. “It is very rare, but